2011-018 – Technology Description Several recent studies suggest that the microbiome bacterial community of an individual’s gut may play a role in obesity by increasing or decreasing that individual’s energy harvesting efficiency of its caloric intake. Obese individuals contain bacterial species that are known to ferment carbohydrates to acetate and other short-chain fatty acids. These fatty acids are... Read More
2009-173 – Insulin-Stimulating Peptides for Diabetes and Metabolic Disorders Mayo Clinic Researchers have developed a series of peptides that have been shown to modulate glucose levels and reduce fibrotic damage to the heart and kidneys in diabetic animal models. These peptides are structural analogs of glucagon-like peptide (GLP) and natriuretic peptides. Application Control of glucose levels in... Read More
2009-172 – Glucagon-like peptide-1 (GLP-1) is derived from the transcription product of the proglucagon gene and is currently used for the management of DM. We have created a peptide with GLP-1 Properties.
2002-226 – Our invention is the use biological, pharmacological or saccharide intervention, genetic modification or selection, for antagonist or modulation of Toll-like receptor 4 (TLR4) or other TLRs for the increase and/or maintenance of bone density, osteoporosis, Paget’s disease, or any disease or condition in which bone loss is a factor.
Modulation of Toll-like Receptor 4 Signaling, or Other TLRs for Treatment or Prevention of Obesity and Excess Fat
2002-225 – Our invention is the use biological, pharmacological or saccharide intervention, genetic modification or selection, for antagonist or modulation of Toll-like receptor 4 (TLR4) or other TLRs for the maintenance, or reduction of fat body mass, obesity or any related conditions or diseases where body fat is a contributing factor.